Statin [orch, phsu]
therapy [ftcn]
C-reactive protein level [lbpr]
Pravastatin [orch, phsu]
Inflammation [patf]
C-reactive protein [aapp, imft]
Evaluation [ftcn]
randomized [resa]
Trial [resa]
Study [mnob]
Context [fndg]
Plasma [bdsu]
Inflammatory [ftcn]
Biomarker [clna]
C-reactive protein [aapp, imft]
CARDIOVASCULAR [bdsy]
Retrospective Studies [resa]
Suggest [idcn]
Station [mnob]
C-reactive protein [aapp, imft]
Low Density Lipoprotein Cholesterol [bacs, strd]
prospective [resa]
Trial [resa]
Directly [qlco]
Evaluate [ftcn]
Anti-inflammatory effect [qlco]
Statins [orch, phsu]
Not available [idcn]
Objective [inpr]
Test [lbpr]
Hypothesis [idcn]
Anti-inflammatory effect [qlco]
C-reactive protein [aapp, imft]
reduction [npop]
Design [acty]
setting [ftcn]
participants [popg]
Community [geoa]
Based [ftcn]
prospective [resa]
randomized [resa]
DOUBLE BLIND [resa]
Trial [resa]
Including [ftcn]
Men [popg]
Women [popg]
Prior [tmco]
History [ocdi]
Cardiovascular disease [dsyn]
Primary Prevention [topp]
Open Label Study [resa]
Including [ftcn]
Patients [podg]
Known [qlco]
Cardiovascular disease [dsyn]
Secondary Prevention [topp]
Provided [acty]
baseline [bodm]
blood samples [bdsu]
Study [mnob]
Conduct [inbe]
Office [mnob]
Based [ftcn]
practices [menp]
interventions [hlca]
participants [popg]
DOUBLE BLIND [resa]
Primary Prevention [topp]
Trial [resa]
Assigned [ftcn]
Receive [qlco]
mg/d [qnco]
Pravastatin [orch, phsu]
N NOS [aapp, imft]
placebo [topp]
N NOS [aapp, imft]
weeks [tmco]
participants [popg]
Secondary Prevention [topp]
Received [qlco]
mg/d [qnco]
OPEN LABEL [resa]
Pravastatin [orch, phsu]
weeks [tmco]
Main [qlco]
outcome measure [qnco]
C-reactive protein level [lbpr]
baseline [bodm]
weeks [tmco]
Primary Prevention [topp]
Trial [resa]
Compared [acty]
placebo [topp]
Pravastatin [orch, phsu]
Reduced [qlco]
C-reactive protein level [lbpr]
P NOS [aapp, imft]
weeks [tmco]
Reflecting [menp]
Decrease [qlco]
mg dl [qnco]
Pravastatin [orch, phsu]
Group [idcn]
C-reactive protein level [lbpr]
Observed [ftcn]
placebo [topp]
Group [idcn]
Seen [qlco]
weeks [tmco]
reduction [npop]
C-reactive protein [aapp, imft]
Pravastatin [orch, phsu]
14 7 [qnco]
P NOS [aapp, imft]
Present [qnco]
subgroups [virs]
Sex [orgf]
Age [orga]
Smoking [inbe]
Status [qlco]
Body Mass Index [diap]
baseline [bodm]
Lipid level [lbtr]
Diabetes [dsyn]
Aspirin [orch, phsu]
Hormone replacement therapy [topp]
Association [menp]
Observed [ftcn]
baseline [bodm]
C-reactive protein [aapp, imft]
baseline [bodm]
End [spco]
Study [mnob]
C-reactive protein [aapp, imft]
End [spco]
Study [mnob]
C-reactive protein [aapp, imft]
Linear [spco]
Regression Analyses [inpr]
C-reactive protein [aapp, imft]
Log [inpr]
Scale [medd]
randomized [resa]
Pravastatin [orch, phsu]
Allocation [acty]
baseline [bodm]
C-reactive protein level [lbpr]
P NOS [aapp, imft]
reductions [npop]
C-reactive protein level [lbpr]
Observed [ftcn]
weeks [tmco]
weeks [tmco]
Secondary Prevention [topp]
treated [topp]
Pravastatin [orch, phsu]
P NOS [aapp, imft]
Conclusions [idcn]
prospective [resa]
Trial [resa]
Pravastatin [orch, phsu]
Reduced [qlco]
C-reactive protein level [lbpr]
weeks [tmco]
Independent [idcn]
Statin [orch, phsu]
Anti-inflammatory effect [qlco]
Addition [ftcn]
Lipid [lipd]
lowering [spco]
effects [qlco]
